

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09.964,992	09/26/2001	Mikal E. Saltveit	UCDA.004.01US	2976
75	90 01/24/2003			
Kevin L. Bastian, Esq			EXAMINER	
Townsend & Townsend & Crew LLP Eighth Floor			BAUM, STUART F	
Two Embarcade San Francisco, (ero Center CA 94111-3834		ART UNIT	PAPER NUMBER
,			1638	_
			DATE MAILED: 01/24/2003	16

Please find below and/or attached an Office communication concerning this application or proceeding.

Mark 1997 Company of the Company

<u> </u>	· · · · · · · · · · · · · · · · · · ·	Application No.	Applicant(s)				
Office Action Summary		09/964,992	SALTVEIT ET AL.				
		Examiner	Art Unit				
		Stuart F. Baum	1638				
	The MAILING DATE of this communication app		with the correspondence address				
Period fo	• •						
THE - Exte after - If the - If NC - Failu - Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication is period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may within the statutory minimum of t vill apply and will expire SIX (6) M cause the application to become	a reply be timely filed hirty (30) days will be considered timely. ONTHS from the mailing date of this communication. ABANDONED (35 U.S C. § 133)				
Status	·¬/	olara i					
1)[Responsive to communication(s) filed on						
2a) 🗌	·	is action is non-final.					
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims	ex parto quayro, 1000 v	5.5. 11, 100 0.0. 210.				
4)	Claim(s) is/are pending in the application	on.					
	4a) Of the above claim(s) is/are withdraw	vn from consideration.					
5)	Claim(s) is/are allowed.						
6)	6) Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
	Claim(s) <u>1-23</u> are subject to restriction and/or e	election requirement.					
	on Papers						
	The specification is objected to by the Examiner						
10)[_]	The drawing(s) filed on is/are: a) accep	· — ·					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner.							
		arniner.					
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)	☐ All b)☐ Some * c)☐ None of: 1.☐ Certified copies of the priority documents	hava baan raasiyad					
	_		Application No.				
* 9	3. Copies of the certified copies of the prior application from the International Bur see the attached detailed Office action for a list of the control of the prior of the	eau (PCT Rule 17.2(a)).				
14) 🗌 A	cknowledgment is made of a claim for domestic	priority under 35 U.S.C	C. § 119(e) (to a provisional application).				
) \square The translation of the foreign language protection \square						
Attachmen	t(s)						
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	w Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)				
S. Patent and Tr							

Application/Control Number: 09/964,992 Page 2

Art Unit: 1638

DETAILED ACTION

Claim 23 has been incorrectly numbered as "claim 24". Original claim 24 has been renumbered as claim 23 according to 37 CFR 1.126

In claims 15-16, 18, and 21-23, SEQ ID NO:'S have been specified that do not correspond to the appropriate nucleic acid or amino acid sequence as claimed. Correction is required.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Applicant is reminded that nucleotide sequences are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute **independent and distinct** inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq (see MPEP 803.04 and 2434).

Applicant is advised to select a corresponding pair of sequences (if appropriate) when electing an Invention (i.e., SEQ ID NO:1 with SEQ ID NO:3 or SEQ ID NO:2 with SEQ ID NO:4)

- I. Claims 1-5, 9-13, 15-17, drawn to a probe and an isolated nucleic acid construct comprising a nucleic sequence encoding an amino acid sequence, transgenic plant or bacterial cell and method of altering phenylalanine ammonia lyase (PAL) levels, classified in class 800, subclass 298 for example.
- II. Claims 6-8 and 21-23, drawn to a kit comprising an antibody, classified in class424, subclass 130.1 for example.
- III. Claim 14, drawn to a degenerate primer pair, classified in class 536, subclass 24.3 for example.

Application/Control Number: 09/964,992

Art Unit: 1638

IV. Claims 18-20, drawn to a method of measuring the relative amount of PAL levels, classified in class 435, subclass 91.1 for example.

Inventions I-III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the isolated nucleic acid of Group I, the kit of Group II and the degenerate primer pair of Group III differ in composition, structure and function.

Inventions II and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the kit can be used for another purpose other than measuring the amount of PAL levels in a sample. For example, detecting the presence of the antibody epitope in invisible ink.

Each of Inventions I-IV are capable of being separately made, independently used, and the patentability of one does not render the others obvious or unpatentable.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, fields of search (literature and sequence), and classification, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/964,992

Art Unit: 1638

Page 4

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stuart Baum whose telephone number is (703) 305-6997. The examiner can normally be reached on Monday-Friday 8:30AM – 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (703) 306-3218. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3014 or (703) 305-3014 for regular communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the legal analyst, Tiffiany Tabb, whose telephone number is (703) 605-1238.

Stuart Baum Ph.D.

January 13, 2003

PHUONG T. BUI PRIMARY FXAMINER / 16/03